STIMOLA CURIOSITA’, PASSIONE E CORAGGIO
The additive effect of ketamine in combination with electroconvulsive stimulation (ECS) in major depressive disorder (MDD): a translational study
PRIN 2022 - Finanziato da MUR
Abstract
Major depressive disorder (MDD) is a disease characterized by a decrease in mood. Ketamine is an antidepressant showing efficacy for treating MDD. Electroconvulsive stimulation (ECS) is an option for MDD non-responders to pharmacological treatments, but it is often accompanied by cognitive side effects.
We will study:
- the ability of ketamine to potentiate the antidepressant effect of the ECS without causing cognitive impairment in a mouse model
- how the combination of ketamine and ECS will impact neuronal circuitries and biomarkers in brain regions involved in MDD
- the ability of ketamine as add-on in ECS to modulate the behavior as well as plasmatic biomarkers levels.
Partenariato
- Libera Università "Vita Salute S. Raffaele" - Milano
- Università degli Studi di Udine
Importo del progetto
Importo totale del progetto Euro 131.176,00
Importo del progetto Uniud Euro 72.299,00
Finanziamento Uniud Euro 13.422,00
Durata
- Dal 18.10.2023
- Al 17.10.2025
Link